Included in the formulation
Pharmacodynamics:The drug has venotonic, angioprotective, venoprotective action.
Increases the tone of the veins (vasoconstrictor effect on the veins is dose-dependent), reduces venous stasis and the volume of venous stasis. Increases the resistance of capillaries (dose-dependent effect), reduces their permeability, improves microcirculation. Has an angioprotective effect. Increases vascular resistance, as well as systolic and diastolic pressure in orthostatic hypertension in the postoperative period. Improves lymphatic drainage.
There are data on the possible efficacy for the prevention of bleeding arising from the use of the intrauterine device and the consequences of phlebectomy.
Pharmacokinetics:Quickly absorbed from the digestive tract, starting from the second hour after administration. Cmax in the plasma is determined after 5 hours. It accumulates in the region of the hollow veins, subcutaneous veins of the lower extremities, to a lesser extent - in the kidneys, liver and lungs, in an insignificant amount - in other organs and tissues.The selective accumulation of diosmin and / or its metabolites reaches a maximum of 9 hours and lasts for the next 96 hours. It does not penetrate the hematoplacental barrier. Excreted mainly in the urine - 79%, bile - 2.4% and feces - 11%.
Indications:Varicose veins of the lower extremities, chronic lymphovenous insufficiency of the lower extremities, hemorrhoids in the acute stage, disturbance of microcirculation.
IX.I80-I89.I83 Varicose veins
IX.I80-I89.I84 Hemorrhoids
IX.I80-I89.I87.2 Venous insufficiency (chronic) (peripheral)
IX.I95-I99.I99 Other and unspecified disorders of the circulatory system
Contraindications:Hypersensitivity, age to 18 years.
Carefully:It should be borne in mind that when exacerbating hemorrhoids, the use of diosmin (it should be short-lived) does not replace the specific treatment of other anal disorders. Proctologic examination and revision of treatment tactics are necessary if the symptoms of hemorrhoids do not disappear after short-term therapy.
Pregnancy and lactation:Experimental studies in animals did not reveal a teratogenic effect of diosmin.In clinical trials (currently) no harmful effects of the use of the drug on the course of pregnancy and fetal development have been established.
The FDA action category is not defined.
For the duration of treatment, breastfeeding should be abandoned (there is no data on the penetration of the drug into breast milk).
Dosing and Administration:Inside. With venous insufficiency - 600 mg in the morning before meals, for 2 months; with severe forms of chronic lymphovenous insufficiency (swelling, pain, convulsions), treatment continues for 3-4 months; In the presence of trophic changes and ulcers, the course is prolonged to 6 months or more. The course is repeated after 2-3 months.
When hemorrhoids in the acute stage - during meals 1200-1800 mg per day, for 7 days, then, if necessary, you can continue 600 mg once a day for 1-2 months.
In the treatment of chronic lymphovenous insufficiency in the II and III trimesters of pregnancy, the drug is canceled 2-3 weeks before the birth.
If one or more doses are missed, then the drug should be continued in the usual dosage.
Side effects:Headache, dyspeptic phenomena, allergic reactions.
Overdose:There is no evidence of an overdose of the drug. Treatment is symptomatic.
Interaction:Clinically significant interactions are not established.
Special instructions:During treatment, it is recommended to avoid long exposure to the sun, to reduce body weight, to walk, in some cases - to wear special stockings to improve blood circulation, since the maximum effect of therapy for venous circulation disorders is provided when combined with a certain lifestyle.